Posted on

cbd stocks 2021

These are the marijuana stocks with the lowest 12-month trailing price-to-sales (P/S) ratio. For companies in the early stages of development or industries suffering from major shocks, this can be substituted as a rough measure of a business’s value. A business with higher sales could eventually produce more profit when it achieves (or returns to) profitability. The P/S ratio shows how much you’re paying for the stock for each dollar of sales generated.

Below we look at the top five marijuana stocks with the best value, the fastest growth, and the most momentum.

The marijuana industry is made up of companies that either support or are engaged in the research, development, distribution, and sale of medical and recreational marijuana. Cannabis has begun to gain wider acceptance and has been legalized in a growing number of nations, states, and other jurisdictions for recreational, medicinal, and other uses. Some of the biggest companies in the marijuana industry include Canopy Growth Corp. (CGC), Cronos Group Inc. (CRON), and Tilray Inc. (TLRY). Many big marijuana companies have continued to post sizable net losses as they focus on investing in equipment to speed up revenue growth.

Best Value Marijuana Stocks

These are the marijuana stocks with the highest year-over-year (YOY) sales growth for the most recent quarter. Rising sales can help investors identify companies that are able to grow revenue organically or through other means, and find growing companies that have not yet reached profitability. In addition, earnings per share can be significantly influenced by accounting factors that may not reflect the overall strength of the business. However, sales growth can also be potentially misleading about the strength of a business, because growing sales on money-losing businesses can be harmful if the company has no plan to reach profitability.

Momentum investing is a factor-based investing strategy in which you invest in a stock whose price has risen faster than the market has as a whole. Momentum investors believe that stocks that have outperformed the market will often continue to do so because the factors that caused them to outperform will not suddenly disappear. In addition, other investors, seeking to benefit from the stock’s outperformance, will often purchase the stock, further bidding its price higher and pushing the stock higher still. These are the stocks that had the highest total return over the past 12 months.

GRWG is top for value and growth, and IIPR is top for momentum

Marijuana stocks, as represented by the ETFMG Alternative Harvest ETF (MJ), have dramatically underperformed the broader market. MJ has provided a total return of -28.6% over the past 12 months, well below the Russell 1000’s total return of 25.2%. These market performance numbers and all statistics in the tables below are as of Jan. 6, 2022.

The comments, opinions, and analyses expressed herein are for informational purposes only and should not be considered individual investment advice or recommendations to invest in any security or to adopt any investment strategy. Though we believe the information provided herein is reliable, we do not warrant its accuracy or completeness. The views and strategies described in our content may not be suitable for all investors. Because market and economic conditions are subject to rapid change, all comments, opinions, and analyses contained within our content are rendered as of the date of the posting and may change without notice. The material is not intended as a complete analysis of every material fact regarding any country, region, market, industry, investment, or strategy.

DISCLAIMER: OTC Stock Review (OTCSR), which owns and operates OTCStockReview.com, is a third- party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. OTCSR is NOT affiliated in any manner with any company mentioned herein. OTCSR and its affiliated companies is a news dissemination solutions provider and are not a registered broker/dealer/analyst/adviser. OTCSR holds no investment licenses and may not sell, offer to sell or offer to buy any security. OTCSR’s market updates, news alerts and corporate profiles are not a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is never to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. OTCSR is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed OTCSR was compensated two thousand dollars for news coverage of current press releases issued by Pure Harvest Corporate Group, Inc. by a non-affiliated third party.

During the global Covid-19 pandemic, medical marijuana was deemed “essential,” which definitely had an impact on increased sales. U.S. legal cannabis sales grew 46% year over year to $17 billion in 2020. The total U.S. economic impact from marijuana sales in 2021 is expected to reach $92 billion – up more than 30% from last year – and upwards of $160 billion in 2025, according to analysis from the recently published MJBizFactbook.

Pure Harvest Corporate Group, Inc. (OTCQB: PHCG) has started getting a lot of attention from cannabis investors, since the Company recently announced Q1 2021 revenues increased by 92.65% from Q4 2020 revenue. Not only did revenues increase, Pure Harvest Corporate Group did more revenues in the first quarter of 2021 than it did in all of 2020. Q1 2021 Revenue was $794,148 versus 2020 Year End Revenue of $735,690. The significant increases are largely attributable to continued growth in sales at the Company’s Colorado marijuana operations located in Dumont, CO. The Company’s Test Kitchen subsidiary began generating revenue with the launch of their white label program and beta product release.

In mid-July, Aurora Cannabis announced it had delivered a cannabis shipment worth nearly C$8 million to Israel, which is one of the largest single shipments of cannabis that Israel has received. The Company said the sale is a significant step in advancing the Company’s international medical business, which is a key strategic priority for Aurora as a global cannabis company. Aurora said with leadership in both Canada and Europe, it is positioned to be a partner of choice in countries like Israel, where THC recreational markets are expected to be around the corner, and non-THC cannabinoids, such as CBD, are advancing toward legalization. Aurora’s brand portfolio includes Aurora, Aurora Drift, San Rafael ’71, Daily Special, AltaVie, MedReleaf, CanniMed, Whistler, and Reliva CBD. For more information on Aurora Cannabis visit www.auroramj.com.

Tilray, Inc. (NASDAQ: TLRY), Pure Harvest Corporate Group, Inc. (OTC: PHCG), Canopy Growth (NASDAQ: CGC), and Aurora Cannabis (NASDAQ: ACB) are four companies that could have major moves in front of them as investors add cannabis stocks to their portfolios.

ATLANTA, Aug. 05, 2021 (GLOBE NEWSWIRE) — As homebound consumers worked out some of their boredom and anxiety with cannabis, shares of many of the main players performed very well in 2020. In 2021, however, cannabis shares have been hot and cold. Many investors are looking down the path to federal legalization for big profits. Federal legalization might not happen, so it is probably better to hope for the best and plan for the worst, as the old saying goes. Regardless of what happens on Capitol Hill, volumes are starting to pick up and we could be getting ready to bounce off this latest correction.

Canopy Growth (NASDAQ: CGC) has the largest market cap of any cannabis stock with a market value of around $7.3 billion. Canopy Growth offers product varieties in high-quality dried flower, oil, softgel capsule, infused beverage, edible, and topical formats, as well as vaporizer devices. Its global medical brand, Spectrum Therapeutics, sells a range of full-spectrum products using its color-coded classification system. Through its Tweed and Tokyo Smoke banners, Canopy Growth has built a loyal following. Canopy Growth has a deal in place to buy U.S. cannabis operator Acreage Holdings to grow its U.S. CBD business. Canopy Growth also purchased AV Cannabis Inc., a Toronto company that makes vapes, gummies and pre-rolls, in a bid to build more brand loyalty with customers.

On July 28, 2021 Tilray reported 2021 fiscal year and fourth quarter results. Net revenue increased 27% to $513 million compared to the prior year net income of $33.6 million. Tilray also posted adjusted EBITDA of $12.3 million, net cash from operating activities of $8.3 million, and positive free cash flow of $3.3 million in Q4. After finalizing the Aphria acquisition, Irwin D. Simon, Tilray’s Chairman and Chief Executive Officer, said, “In a very short period of time since our business combination was finalized, we transformed and strengthened Tilray, delivered solid results amid continued COVID-19 lockdowns and restrictions and achieved $35 million in synergies to date – well on our way to delivering $80 million in cost savings over the next 16 months.” For more information on Tilray, Inc. visit www.tilray.com

Tilray, Inc. (NASDAQ: TLRY) produces high-quality cannabis and cannabis-derived products primarily for global recreational adult-use. Tilray has off and on been the subject of speculation by the players at Wall Street Bets. Tilray offers a broad-based portfolio of brands and adult-use products through its wholly owned subsidiary, High Park Holdings Ltd. The Company also supplies high-quality medical cannabis products to tens of thousands of patients in 17 countries on five continents through its subsidiaries in Australia, Canada, Germany, Latin America and Portugal, and through agreements with established pharmaceutical distributors. Analysts at Cantor Fitzgerald recently upgraded the stock after its merger with Aphria in May. Following the merger, the combined Tilray/Aphria has the largest global geographic footprint in the industry, low-cost production facilities, and a wealth of international growth opportunities.